Vertex Pharmaceuticals Incorporated

Sümbol: VRTX

NASDAQ

400.16

USD

Turuhind täna

  • 28.4897

    P/E suhe

  • 1.0778

    PEG suhe

  • 103.36B

    MRK Cap

  • 0.00%

    DIV tootlus

Vertex Pharmaceuticals Incorporated (VRTX) Finantsaruanded

Diagrammil näete Vertex Pharmaceuticals Incorporated (VRTX) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 1515.622 M, mis on 0.661 % gowth. Kogu perioodi keskmine brutokasum on 1332.322 M, mis on 0.555 %. Keskmine brutokasumi suhtarv on 0.989 %. Ettevõtte eelmise aasta tulemuse puhaskasv on 0.090 %, mis on võrdne -0.366 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

Bilanss

Sukeldudes Vertex Pharmaceuticals Incorporated fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus 0.252. Käibevara valdkonnas on VRTX aruandlusvaluutas 14144.2. Märkimisväärne osa neist varadest, täpsemalt 11221.5, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust 0.041%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 2596.4, kui neid on, aruandlusvaluutas. See näitab erinevust 2512.072% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 724.7 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on 0.441%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud 17580.4 aruandlusvaluutas. Selle aspekti aastane muutus on 0.264%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 1563.4, varude hind on 738.8 ja firmaväärtus 1088, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 839.9.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996199519941993199219911990

balance-sheet.row.cash-and-short-term-investments

44800.111221.510778.57524.9
6658.9
3808.3
3168.2
2088.7
1434.6
1042.5
1387.1
1465.1
1321.2
968.9
1031.4
1284.9
832.1
460.9
704.6
361.2
392.3
583.2
635
743.2
388.6
31.5
24.2
71.5
34.9
28.4
71.6
28.6
11.6
27.6
4.4

balance-sheet.row.short-term-investments

25137.9849.2274.5729.9
670.7
699
518.1
423.3
250.6
327.7
761.8
895.8
831.8
493.6
788.2
838.3
443
105.2
491.5
283.1
337.3
485
526.9
554
66.5
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

6206.11563.41442.21136.8
885.4
633.5
409.7
281.3
201.1
177.6
73
85.5
143.3
183.1
12.5
9.6
23.5
31.3
62.9
20.6
11.9
7.3
13.2
20.3
12.3
5.9
0
0
0
0
0
0
0
0
0

balance-sheet.row.inventory

2566.1738.8460.6353.1
280.8
167.5
124.4
111.8
77.6
56.1
30.8
14.1
30.5
112.4
0
0
0
0
0
0
0
0
4.3
6.6
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

2106.3620.574.4187.2
308.4
213.5
74
64
16.8
12.1
57.2
23.8
24.7
983.8
13.1
12.5
12
4.7
3.9
3.3
2.5
3.3
4
6
2.3
157.8
224.5
210.1
97.3
59.5
35.3
24.5
32.4
24.1
0.2

balance-sheet.row.total-current-assets

55678.614144.212681.39014.8
7825
4609.3
3702.3
2483.3
1761
1355.1
1548.1
1588.6
1589.6
1331.3
1057
1307
867.6
496.9
771.4
385.1
406.7
593.8
656.6
776.1
403.2
195.2
248.7
281.6
132.2
87.9
106.9
53.1
44
51.7
4.6

balance-sheet.row.property-plant-equipment-net

5782.11452.91108.41094.1
958.5
745.1
812
789.4
698.4
697.7
715.8
696.9
433.6
133.2
72.3
62.3
68.3
66.5
61.5
54.5
64.2
80.1
96
80.4
28.1
24.5
14.5
11.1
8.7
7.8
8.5
7.7
6.9
5
4.4

balance-sheet.row.goodwill

4352108810881402.2
1402.2
1402.2
50.4
50.4
50.4
50.4
39.9
31
31
31
26.1
26.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

2650.7839.9603.6400
400
400
0
29
284.3
284.3
29
105.8
663.5
663.5
518.7
518.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

7002.71927.91691.61402.2
1402.2
1402.2
50.4
79.4
334.7
334.7
68.9
31
694.5
694.5
544.8
544.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

6735.22596.499.485.8
20.8
44.2
0
20.4
20.3
0
0
7.5
0
0
0
0
0
0
0
18.9
18.9
18.9
26.4
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

6439.11812.11246.9934.5
882.8
1190.8
1499.7
-20.4
-20.3
0
0
-7.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

2142.1796.71323.3901.1
662.5
326.9
181.5
193.9
99.7
109.5
3.4
2.6
41.6
45.4
51.3
41.4
44.6
38.1
88.6
90.5
55.7
31.7
36.7
68.7
341.5
12.7
3.1
2.9
2.6
3.3
0.8
0.2
0.1
0.4
0.2

balance-sheet.row.total-non-current-assets

28101.285865469.64417.7
3926.8
3709.2
2543.6
1062.7
1132.8
1142
788.2
730.5
1169.7
873
668.4
648.5
112.9
104.6
150.2
163.9
138.7
130.6
159.1
149
369.7
37.2
17.6
14
11.3
11.1
9.3
7.9
7
5.4
4.6

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

83779.822730.218150.913432.5
11751.8
8318.5
6245.9
3546
2893.8
2497
2336.3
2319
2759.3
2204.3
1725.4
1955.5
980.5
601.5
921.6
549
545.5
724.4
815.7
925.1
772.9
232.4
266.3
295.6
143.5
99
116.2
61
51
57.1
9.2

balance-sheet.row.account-payables

1427364.9303.9195
155.1
87.6
111
74
61.5
74.9
71.2
49.3
101.3
74.6
35.9
37
51.8
32.8
15.4
6.2
6.7
12.3
16.7
11.6
3.8
3
2.8
4.2
1.4
3
1.4
3.5
0.7
0.8
0

balance-sheet.row.short-term-debt

83.783.789.446.9
42.4
30.3
9.8
22.5
319.4
87
32
16.9
13.7
195.4
137
32.1
105.9
20
103.8
59.6
94.7
4.7
2.2
4.6
2.4
2.4
2.8
2.5
2.9
2.1
1.7
1.8
1.8
1.2
0.8

balance-sheet.row.tax-payables

99.599.5123.3211.3
104.2
72.3
0
0
6.9
31
10
8.4
0.7
12.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

3026.2724.7471.6556.7
581.5
577.4
567.2
563.9
838.2
820.6
825.3
440.9
672.6
400
400
153.8
287.5
0
20
180.1
335
340.7
325.9
323
347.3
4.7
7
5.9
5.6
4.9
4.7
4.2
3.3
2.1
2.4

Deferred Revenue Non Current

-924.1-924.100
0
88.8
82.6
80.2
12.6
26
45.3
71
123.8
118.1
160
38.2
247.5
101.2
116.3
0.9
18.3
51.8
46.6
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

924.1---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

11844.12928.51877.71460
1171
1024.3
40.6
473.2
-452.3
328.1
247.6
310.1
290.1
405.6
227.3
296.9
21.3
121
98
3
4.7
114.4
33.8
35.8
32.4
13.1
7.5
7
2.8
3.7
2.9
2
1.4
0.7
0.8

balance-sheet.row.total-non-current-liabilities

62591602.41807.61458.9
1504.9
1028.7
1095.2
1503.7
1547.6
1404.4
1240.1
962.6
1524.9
400
746.7
192
525
130.9
164.6
209.6
356.3
392.5
372.5
358.2
347.3
4.7
7
5.9
5.6
4.9
4.7
4.2
3.2
2.2
2.4

balance-sheet.row.other-liabilities

0000
0
0
0
-807.3
0
-506.3
-368.3
-397.8
-432.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

3026.2724.7471.6556.7
581.5
577.4
567.2
563.9
541.3
525.2
530.5
440.9
272.6
0
0
32.1
0
0
0
0
0
25.7
10.9
8
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

19784.15149.84238.23332.5
3065
2233.2
1810.7
1503.7
1555.6
1404.4
1240.1
962.6
1524.9
1238.8
1221.5
858.5
741.6
330.2
415.6
309.8
510
531.6
437.1
449.8
386
23.2
20.1
19.6
12.7
13.7
10.7
11.5
7.1
4.9
4

balance-sheet.row.preferred-stock

0000
0
0
0
13.7
181.6
152.7
21.2
0
0
0
0
0.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

520.82.62.62.5
2.6
2.6
2.5
2.5
2.5
2.4
2.4
2.3
2.1
2.1
2
2
1.5
1.3
1.2
1.1
0.8
0.8
0.8
0.8
0.6
0.3
0
0
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

34676.910142.46522.83200.8
858.7
-1853
-2989.5
-5119.7
-5373.8
-5261.8
-4705.4
-3966.9
-3521.9
-3414.8
-3444.4
-2689.8
-2047.6
-1587.8
-1196.5
-989.6
-786.2
-619.9
-423.2
-314.5
-230.5
-190.8
-149.9
-116.8
-96.9
-56.9
-35.4
-17.8
-19.9
-11.4
-6.2

balance-sheet.row.accumulated-other-comprehensive-income-loss

-70.2-14.30.815.9
-68.5
-2
0.7
-11.6
21.2
1.8
0.9
-0.3
-0.6
-1.1
-1.1
-0.6
3.2
0.9
-1
-16.3
-13
1.6
6.8
11.1
3.6
-1.1
-28.1
-23.6
-20
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

28868.27449.77386.56880.8
7894
7937.6
7421.5
7157.4
6506.8
6197.5
5777.2
5321.3
4519.4
4200.7
3947.4
3784.8
2281.8
1856.9
1702.1
1244
833.8
810.4
794.2
858
659.4
434.1
424.2
416.4
247.7
142.2
140.9
67.3
63.8
63.6
11.4

balance-sheet.row.total-stockholders-equity

63995.717580.413912.710100
8686.8
6085.2
4435.2
2042.3
1338.2
1092.7
1096.2
1356.4
999.2
786.8
504
1096.9
238.9
271.3
505.9
239.2
35.4
192.8
378.6
475.4
386.9
209.2
246.2
276
130.8
85.3
105.5
49.5
43.9
52.2
5.2

balance-sheet.row.total-liabilities-and-stockholders-equity

83779.822730.218150.913432.5
11751.8
8318.5
6245.9
3546
2893.8
2497
2336.3
2319
2759.3
2204.3
1725.4
1955.5
980.5
601.5
921.6
549
545.5
724.4
815.7
925.1
772.9
232.4
266.3
295.6
143.5
99
116.2
61
51
57.1
9.2

balance-sheet.row.minority-interest

0000
0
0
0
13.7
181.6
153.7
21.2
0
235.2
178.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

63995.717580.413912.710100
8686.8
6085.2
4435.2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

83779.8---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

31873.13445.6274.5729.9
670.7
699
518.1
443.7
270.9
327.7
761.8
895.8
831.8
493.6
788.2
838.3
443
105.2
491.5
302
356.2
503.9
553.3
554
66.5
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-debt

3109.9808.4561556.7
581.5
577.4
567.2
563.9
838.2
820.6
825.3
440.9
672.6
400
537
153.8
287.5
20
123.8
180.1
335
345.4
328.1
327.6
349.7
7.1
9.8
8.4
8.5
7
6.4
6
5.1
3.3
3.2

balance-sheet.row.net-debt

-37813.6-9563.9-9943-6238.3
-5406.7
-2532
-2083
-1101.5
-345.7
105.8
200
-128.4
183.2
-75.3
293.8
-292.8
-101.6
-335.7
-89.4
102.1
280
247.2
220
138.4
27.6
-24.4
-14.4
-63.1
-26.4
-21.4
-65.2
-22.6
-6.5
-24.3
-1.2

Rahavoogude aruanne

Vertex Pharmaceuticals Incorporated finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab -0.165 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 134.6, mis tähistab 0.000 erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli -3141700000.000. See on 8.784 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 181.3, 6.1, -44.9, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte 0 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui -224.3, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997199619951994199319921991

cash-flows.row.net-income

3619.63619.633222342.1
2711.6
1176.8
2087.1
91.6
-84
-588.2
-742.7
-687.5
-51.1
41.2
-754.6
-642.2
-459.9
-391.3
-206.9
-203.4
-166.2
-196.8
-108.6
-66.2
-39.7
-41
-33.1
-19.8
-40
-21.5
-17.6
2
-8.5
-5.1

cash-flows.row.depreciation-and-amortization

181.3181.3148.3125.6
109.5
106.9
72.4
61.4
61.4
62.3
63.3
48.4
38.2
35
30.5
30.1
32.2
27.5
25.9
27.3
29.6
23.4
25.4
18
9.1
6.3
4.5
3.6
3.2
3.7
3.5
3.9
2.8
1.8

cash-flows.row.deferred-income-tax

-536.5-536.5-275.9-154.6
277.3
167.4
-1512.3
-120.5
17
3.3
0.3
-285.1
36.7
-7.5
54.9
-2.2
0
-59.1
-50.2
-7.5
-4.2
-3.1
-1.5
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

581.2581.2491.3441.4
429.5
360.5
325
290.7
237.7
231
177.5
127.3
114.3
126.8
97.7
86.7
63
59.4
39.1
7.5
4.2
3.1
1.5
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

-265.7-265.7340.8-105.2
-54.5
-66.1
238
15.3
-2.1
-86
-11.1
-5.1
-13.8
-193.1
-63.8
61.4
138.8
47.3
123.1
-52.1
-12.7
68.9
0.9
41.1
9.8
1.5
-1.9
6.9
-3.3
1.9
-0.6
2.7
0.4
0.8

cash-flows.row.account-receivables

-84.1-84.1-358.6-274.7
-223.4
-225.6
-108.2
-71.8
-33
-104.8
7.4
53.4
39.9
-170.6
-2.9
13.9
7.8
31.6
-42.3
-8.7
-4.6
1.6
13.6
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-322.9-322.9-136.4-92.8
-132
-64
-32
-45
-16.4
-23.1
-16.5
7.1
-29.9
-111.4
6.2
9.5
-3.2
19.5
48.2
0
0
70.8
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.account-payables

48.748.7120.831.9
51.3
-22.8
36.6
8.8
-11.7
-1.7
25
-49.2
14.9
37.5
-1.2
-15.1
19
17.4
9.2
-0.5
-5.6
-2.2
3.2
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

-46.392.6715230.4
249.7
246.3
341.6
123.3
59.2
43.8
-27.1
-16.3
-38.7
51.5
-65.9
53.1
115.1
-21.2
108
-42.9
-2.5
-1.2
-16
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-non-cash-items

-42.6-42.6103.4-5.8
-220
-176.2
60
506.4
6.1
12
-0.5
750.4
143.6
141.3
0
38.6
-0.6
63.7
46.6
56.1
7.2
-63.2
2.8
-0.9
4.1
1.4
-0.6
-0.1
-0.2
-0.1
0
0
0
0

cash-flows.row.net-cash-provided-by-operating-activities

3537.3000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-258.4-258.4-204.7-235
-259.8
-75.5
-95.5
-259.4
-56.6
-45.3
-51.2
-51.4
-71.1
-94.6
-38.1
-23.5
-32.2
-32.4
-32.4
-17
-12.5
-17.4
-41.2
-53.9
-11.9
-16.2
-7.9
-6
-4
-5.4
-1.9
-1.8
-1.5
-1.2

cash-flows.row.acquisitions-net

55.9-6.1-295.977
-418.2
-1154.2
0
-160
0
-80
-10
0
0
-60
0
-87.4
0
33
0
0
0
97.1
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

-3848.5-3817.5-740.5-605.2
-450.7
-576.5
-515.4
-532.6
-629.7
-633
-1424.2
-2412.4
-1705.8
-721.5
-1234.7
-1186.7
-755.4
-318
-508.1
-236.5
-148.5
-555.8
-703
-1252.8
-1312.8
-366
-507.5
-303.6
-73
-61.9
-83.9
-48.3
-39.7
0

cash-flows.row.sales-maturities-of-investments

934.2934.2920499.3
809.9
570.9
431.6
369.2
757.6
1067.4
1557.9
2348.3
1367.9
1016
1284.8
788.3
427.6
755.6
302.4
243.4
292.4
594
728
1176.2
1088.6
428.9
495.3
191
36.2
38.3
72.3
56.8
31.6
-23.9

cash-flows.row.other-investing-activites

-24.96.10-77
418.2
0
-22.8
145.1
33.2
-40.2
1.4
61.4
-16.8
72.5
-4.7
0.6
-0.7
-33
29.6
8.3
-23.9
1.6
0.2
-14.6
-0.2
-10.3
-0.3
-0.2
0.4
0
-0.6
0
0.2
-0.1

cash-flows.row.net-cash-used-for-investing-activites

-3141.7-3141.7-321.1-340.9
99.4
-1235.3
-202.2
-437.7
104.5
268.9
74
-54.1
-425.8
212.4
7.3
-508.7
-360.6
405.2
-208.5
-1.7
107.4
119.6
-16
-145.1
-236.3
36.4
-20.4
-118.8
-40.4
-29
-14.1
6.7
-9.4
-25.2

cash-flows.row.debt-repayment

-44.9-44.9-85.5-47
-42.3
-39.2
-33.4
-319.3
-93
-20.3
-81.7
-83.7
-21.5
-250
0
-0.1
-20
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

134.6134.6186.3102
264.9
343.2
289.3
344.8
68.2
185.6
274.6
265.9
191.7
124.9
33.4
849.2
362.1
32
366
32.2
8.7
12
13.3
19.7
42.4
5.5
2.8
164.9
85.5
1.1
73.8
3.6
0.1
51.9

cash-flows.row.common-stock-repurchased

-650.5-427.6-172-1561.3
-739.4
-192
-350
0
0
0
0
0
0
0
0
290.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

000-102
-264.9
-10
-20.8
0
0
0
0
0
0
0
0
-290.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

72.6-224.33.5130.3
276.4
24.8
43.8
42.9
158.1
23.7
304.5
-1.3
2
0.9
391.6
149.9
278.6
-42.2
-0.2
165.3
-17.4
25.5
0.5
-23.6
501.6
-2.7
1.4
-0.1
1.6
0.6
-1.9
-2
-1.3
-1

cash-flows.row.net-cash-used-provided-by-financing-activities

-562.2-562.2-67.7-1478
-505.3
126.8
-71.2
68.4
133.3
188.9
497.4
180.9
172.2
-124.2
425.1
999
620.7
-10.2
365.9
197.5
-8.6
37.5
13.8
-4
544
2.8
4.2
164.8
87.1
1.7
71.9
1.6
-1.2
50.9

cash-flows.row.effect-of-forex-changes-on-cash

26.926.9-29.2-13.4
20.6
1.6
-6.2
5.8
-4.7
-2.8
-2.2
4.7
-0.1
0.2
-0.4
-5.1
-0.2
0
0.2
-0.6
0.2
0.6
0.6
-0.3
-0.5
-0.1
51.5
128.2
80.7
45
28.8
-15.3
14.7
27.7

cash-flows.row.net-change-in-cash

-139.7-139.73711.9811.2
2868.2
462.4
990.7
481.5
469.2
89.5
56
79.9
14.1
232.1
-203.5
57.5
33.5
142.5
135.1
23
-43.2
-9.9
-81.1
-157.5
290.5
7.3
4.2
164.8
87.1
1.7
71.9
1.6
-1.2
50.9

cash-flows.row.cash-at-end-of-period

40937.910372.3105126800.1
5988.8
3120.7
2658.3
1665.4
1183.9
714.8
625.3
569.3
489.4
475.3
243.2
446.7
389.1
355.7
213.2
78
55
98.2
108.1
189.2
322.1
31.5
75.7
199.7
115.5
73.3
100.5
13.2
26.4
55.3

cash-flows.row.cash-at-beginning-of-period

41077.6105126800.15988.9
3120.7
2658.3
1667.5
1183.9
714.8
625.3
569.3
489.4
475.3
243.2
446.7
389.1
355.7
213.2
78
55
98.2
108.1
189.2
346.7
31.5
24.2
71.5
34.9
28.4
71.6
28.6
11.6
27.6
4.4

cash-flows.row.operating-cash-flow

3537.33537.34129.92643.5
3253.5
1569.3
1270.3
844.9
236.1
-365.4
-573.1
-60.7
267.8
143.7
-635.4
-427.6
-226.5
-252.5
-22.5
-172.1
-142.2
-167.6
-79.5
-8.1
-16.6
-31.8
-31.1
-9.4
-40.3
-16
-14.7
8.6
-5.3
-2.5

cash-flows.row.capital-expenditure

-258.4-258.4-204.7-235
-259.8
-75.5
-95.5
-259.4
-56.6
-45.3
-51.2
-51.4
-71.1
-94.6
-38.1
-23.5
-32.2
-32.4
-32.4
-17
-12.5
-17.4
-41.2
-53.9
-11.9
-16.2
-7.9
-6
-4
-5.4
-1.9
-1.8
-1.5
-1.2

cash-flows.row.free-cash-flow

3278.93278.93925.22408.5
2993.7
1493.9
1174.8
745.5
179.5
-410.7
-624.3
-170.5
196.7
49.1
-673.5
-451.1
-258.7
-284.9
-54.9
-189
-154.7
-185
-120.8
-62
-28.6
-48
-39
-15.4
-44.3
-21.4
-16.6
6.8
-6.8
-3.7

Kasumiaruande rida

Vertex Pharmaceuticals Incorporated tulud muutusid võrreldes eelmise perioodiga 0.102%. VRTX brutokasum on teatatud 8576.8. Ettevõtte tegevuskulud on 4826.6, mille muutus võrreldes eelmise aastaga on 38.496%. Kulud amortisatsioonikulud on 181.3, mis on 3.796% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 4826.6, mis näitab 38.496% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab -0.129% kasvu võrreldes eelmise aastaga. Tegevustulu on 3750.2, mis näitab -0.129% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on 0.090%. Eelmise aasta puhaskasum oli 3619.6.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996199519941993199219911990

income-statement-row.row.total-revenue

9869.298398930.77574.4
6205.7
4162.8
3047.6
2488.7
1702.2
1032.3
580.4
1212
1527
1410.6
143.4
102
175.5
199
216.4
160.9
102.7
69.1
161.1
167.5
78.1
61.6
44.4
43.8
13.3
22.1
19.6
27.9
3.8
3.2
2.3

income-statement-row.row.cost-of-revenue

1262.21262.21080.3904.2
736.3
547.8
409.5
275.1
210.5
125.5
61
130.3
279.9
80.5
12.7
14.2
15.7
13.9
12.2
10.1
5.6
3.1
28.3
39.6
4.1
-3.4
-4.5
-3.6
-3.2
-3.7
-3.5
-3.9
-2.8
-1.8
0

income-statement-row.row.gross-profit

86078576.87850.46670.2
5469.4
3615.1
2638.1
2213.5
1491.7
906.8
519.4
1081.7
1247.2
1330.1
130.6
87.8
159.8
185.1
204.2
150.8
97.1
66
132.8
127.9
74
65
48.9
47.4
16.5
25.8
23.1
31.8
6.6
5
2.3

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

3160.1---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

-22.8-22.8-164.84.9
296.4
192.2
-0.8
-81.4
4.1
-6.7
30.4
-72.7
45
124.8
0
0
0
0
0
0
0
0
0
0
0
6.3
4.5
3.6
3.2
3.7
3.5
3.9
2.8
1.8
0

income-statement-row.row.operating-expenses

4296.74826.634853891.2
2600
2413
1974.1
1820.7
1480.5
1373.3
1160.9
1281.1
1243
1108.4
825.2
680
618.2
597.8
429.6
292.5
234.3
238.7
252.4
196
112.7
104.6
81.3
66.6
46.3
52.3
43.8
30.6
16.6
10.6
6.4

income-statement-row.row.cost-and-expenses

5558.96088.84565.34795.4
3336.3
2960.8
2383.6
2095.8
1691
1498.8
1221.9
1411.4
1522.9
1188.9
837.9
694.2
633.9
611.7
441.7
302.6
239.9
241.8
280.7
235.6
116.8
101.2
76.8
63
43.1
48.6
40.3
26.7
13.8
8.8
6.4

income-statement-row.row.interest-income

614.7614.7144.64.9
22.2
63.7
0
0
0
0
0
0
1.9
1.9
2
5
16.3
0
23
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

44.144.154.861.5
58.2
58.5
34.1
57.5
81.4
84.2
72.9
22.7
14.7
36.6
19.3
13.2
13.5
0
-8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

124.2629.6-75-51.7
260.5
197.4
-29.6
-351
2.9
-8.9
-20.5
-776.7
-1.8
-124.7
-42.7
-49.4
-1.5
-7.1
2.4
-23.5
-3.7
-82.8
-0.1
-26.1
-14.9
-0.7
0
0
-9.7
5.5
3.6
1.4
2
0.8
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

-22.8-22.8-164.84.9
296.4
192.2
-0.8
-81.4
4.1
-6.7
30.4
-72.7
45
124.8
0
0
0
0
0
0
0
0
0
0
0
6.3
4.5
3.6
3.2
3.7
3.5
3.9
2.8
1.8
0

income-statement-row.row.total-operating-expenses

124.2629.6-75-51.7
260.5
197.4
-29.6
-351
2.9
-8.9
-20.5
-776.7
-1.8
-124.7
-42.7
-49.4
-1.5
-7.1
2.4
-23.5
-3.7
-82.8
-0.1
-26.1
-14.9
-0.7
0
0
-9.7
5.5
3.6
1.4
2
0.8
0

income-statement-row.row.interest-expense

44.144.154.861.5
58.2
58.5
34.1
57.5
81.4
84.2
72.9
22.7
14.7
36.6
19.3
13.2
13.5
0
-8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

989.2181.337.86.7
331.8
260.3
72.4
61.4
61.4
62.3
63.3
48.4
38.2
35
30.5
30.1
32.2
27.5
25.9
27.3
29.6
23.4
25.4
18
9.1
6.3
4.5
3.6
3.2
3.7
3.5
3.9
2.8
1.8
0

income-statement-row.row.ebitda-caps

4791.5---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

3802.33750.24307.42782.1
2856.3
1197.6
635.1
123.2
9.9
-468.7
-692.4
-903.4
2.3
113.8
-696.1
-613.4
-462.7
-419.8
-229
-149.9
-154.8
-264.5
-119.6
-91.8
-38.7
-39.6
-32.4
-19.2
-29.8
-26.5
-20.7
1.2
-10
-5.6
-4.1

income-statement-row.row.income-before-tax

4379.84379.84232.42730.4
3116.8
1394.9
600.2
-15.7
-67.4
-559.6
-734.9
-976.1
-12.4
60.4
-754.6
-642.2
-464.2
-426.9
-206.9
-173.4
-158.5
-347.3
-119.7
-117.9
-53.6
-40.3
0
0
-39.5
-21
-17.1
2.1
-8
-4.8
0

income-statement-row.row.income-tax-expense

760.2760.2910.4388.3
405.2
218.1
-1486.9
-107.3
16.7
30.4
7
-288.6
38.8
19.3
19.3
19.3
-30.7
-21.4
-18.5
61.7
29
24.1
-11
-1.9
1
1.4
0.7
0.6
10.2
-5
-3.1
0.1
-1.5
-0.5
4.3

income-statement-row.row.net-income

3619.63619.633222342.1
2711.7
1176.8
2096.9
263.5
-112.1
-558.1
-738.6
-445
-107
29.6
-754.6
-641.6
-459.9
-391.3
-206.9
-203.4
-166.2
-196.8
-108.6
-66.2
-39.7
-41
-33.1
-19.8
-40
-21.5
-17.6
2
-8.5
-5.1
-4.3

Korduma kippuv küsimus

Mis on Vertex Pharmaceuticals Incorporated (VRTX) koguvara?

Vertex Pharmaceuticals Incorporated (VRTX) koguvara on 22730200000.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on 5001200000.000.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.872.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on 12.724.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on 0.367.

Mis on ettevõtte kogutulu?

Kogutulu on 0.385.

Mis on Vertex Pharmaceuticals Incorporated (VRTX) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on 3619600000.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 808400000.000.

Mis on tegevuskulude arv?

Tegevuskulud on 4826600000.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 10372300000.000.